Researchers looked at national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need by generating rates of past-year opioid abuse or dependence using Substance Abuse and Mental Health Services Administration data. Additional parameters included maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more. The researchers used the findings to identify gaps and inform policy decisions. In 2012, the national rate of opioid abuse was 891.8 per 100,000 people aged 12 years or older. Maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs was 420.3 and 119.9, respectively. Ninety-six percent of states had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates. Thirty-eight states reported at least 75% of their OTPs were operating at 80% capacity or more. The researchers, led by FDA's Christopher M. Jones, concluded these were significant gaps that require new strategies in order to increase the number of OA-MAT providers.